[71]
Abbott says that Prothonotary Milczynski's reasons correctly follow
Sierra Club
, and her findings flow naturally from the evidence, until the very last paragraph:
"Novopharm has not established to my satisfaction that all of the material in the ANDS should be treated as confidential, the only exceptions being information about the comparative bioequivalence of Novopharm's lansoprazole 15 mg and 30 mg delayed-release capsules, and the specific formulation of the capsules' non-medicinal ingredients, exceptions that appeared to be acknowledged (if not conceded) by the Applicants."